Scientists at Johns Hopkins have uncovered a surprising new way to influence brain activity by targeting a long-mysterious class of proteins linked to anxiety, schizophrenia, and movement disorders.
Johns Hopkins researchers found that delta-type ionotropic glutamate receptors (GluDs) play a key role in regulating neuronal ...
About the FALCON Trial FALCON is a first-in-human, open-label, multi-center Phase 1b clinical trial designed to evaluate the safety and tolerability of SGT-212 in participants aged 18-40 who have been ...
Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company” or "Solid”), a life sciences company developing precision genetic ...
Koch, who studied vision, thought that by measuring people's brain responses as they looked at special optical illusions, ...
Belfast News Letter on MSN
Vital regional neuromuscular service offers lifeline to patients at Thompson House Hospital
A “busy person” all his life, 73-year-old Gerard ‘Gerry’ Heaney from Craigavon was diagnosed in 2018 with the rare and ...
Asianet Newsable on MSN
Hidden brain protein found to control how brain cells communicate
Scientists reveal the GluD brain protein's active role, offering new hope for mental health. Discover how this breakthrough ...
Miami neuroscience research duo discovered how to restore electrical activity in brain cells linked to autism spectrum disorder ...
Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular ...
SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected ...
The NHS has important information for anyone who has been prescribed clonazepam - a common medication used to treat a variety of conditions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback